Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Amortization of Deferred Charges: 2014-2023

Historic Amortization of Deferred Charges for Cartesian Therapeutics (RNAC) over the last 10 years, with Dec 2023 value amounting to $455,000.

  • Cartesian Therapeutics' Amortization of Deferred Charges fell 139.39% to -$78,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $631,000, marking a year-over-year decrease of 36.20%. This contributed to the annual value of $455,000 for FY2023, which is 52.26% down from last year.
  • Per Cartesian Therapeutics' latest filing, its Amortization of Deferred Charges stood at $455,000 for FY2023, which was down 52.26% from $953,000 recorded in FY2022.
  • Over the past 5 years, Cartesian Therapeutics' Amortization of Deferred Charges peaked at $1.0 million during FY2021, and registered a low of $402,000 during FY2019.
  • Its 3-year average for Amortization of Deferred Charges is $806,667, with a median of $953,000 in 2022.
  • In the last 5 years, Cartesian Therapeutics' Amortization of Deferred Charges soared by 63.23% in 2021 and then slumped by 52.26% in 2023.
  • Yearly analysis of 5 years shows Cartesian Therapeutics' Amortization of Deferred Charges stood at $402,000 in 2019, then spiked by 54.23% to $620,000 in 2020, then spiked by 63.23% to $1.0 million in 2021, then dropped by 5.83% to $953,000 in 2022, then slumped by 52.26% to $455,000 in 2023.